Emma Allen-Vercoe
Canada Research Chair, Human Gut Microbiome Function and Host
Professor
College of Biological Science
Department of Molecular and Cellular Biology
Guelph, Ontario
eav@uoguelph.ca
Office:
(519) 824-4120 ext. 53366
(519) 824-4120 ext. 54478
Bio/Research
Research in Dr. Allen-Vercoe's lab focuses on the study of the normal human gut microbiota, both in disease and in health.
Allen-Vercoe has developed a specific platform for the study of whole microbial ecosystems, dubbed ‘Robogut’ to examine ecosystem function and output in unpreceden...
Click to Expand >>
Allen-Vercoe has developed a specific platform for the study of whole microbial ecosystems, dubbed ‘Robogut’ to examine ecosystem function and output in unpreceden...
Click to Expand >>
Bio/Research
Research in Dr. Allen-Vercoe's lab focuses on the study of the normal human gut microbiota, both in disease and in health.
Allen-Vercoe has developed a specific platform for the study of whole microbial ecosystems, dubbed ‘Robogut’ to examine ecosystem function and output in unprecedented detail. Current projects include the study of the gut microbiota in neonatal necrotizing enterocolitis, Clostridioides difficile (C. diff) infection, diabetes, and inflammatory bowel diseases.
Allen-Vercoe is co-founder and CSO of NuBiyota, a company created to develop the concept of bacterial ecosystem therapeutics for the treatment of diseases related to gut microbial dysbiosis.
Click to Shrink <<
Allen-Vercoe has developed a specific platform for the study of whole microbial ecosystems, dubbed ‘Robogut’ to examine ecosystem function and output in unprecedented detail. Current projects include the study of the gut microbiota in neonatal necrotizing enterocolitis, Clostridioides difficile (C. diff) infection, diabetes, and inflammatory bowel diseases.
Allen-Vercoe is co-founder and CSO of NuBiyota, a company created to develop the concept of bacterial ecosystem therapeutics for the treatment of diseases related to gut microbial dysbiosis.
Click to Shrink <<